IMR Press / FBL / Special Issues / 1395608237923291137

Gestational Diabetes

Submission deadline: 01 December 2021
Special Issue Editors
Marina Ivanišević, MD
Clinical Department of Obstetrics and Gynecology, Zagreb University Hospital Center, School of Medicine, University of Zagreb, Zagreb, Croatia
Interests: Maternal-fetal medicine; Reproductive medicine; Diabetes in pregnancy, Fetal growth, Hypertension in pregnancy
Special Issue Information

Dear Colleagues,

Gestational diabetes mellitus (GDM) is any stage of glucose intolerance initially or first recognized during pregnancy. GDM is due to reduced insulin sensitivity or increased insulin resistance in the pregnant woman's body. Undocumented or uncontrolled GDM can have severe consequences for the mother and child. International Diabetes Federation estimates that approximately 22 million pregnant women during the year 2017 were exposed to some form of hyperglycemia during pregnancy, which is about 16.8% of live-born children from these pregnancies. As with other forms of diabetes, incidence during pregnancy is also associated with age. Almost every fourth, i.e., 23% of pregnant women over 35, is burdened with GDM. The T2DM rate is steadily increasing, preventive measures are limited, as it is most commonly after six weeks of birth that it completely forgets the control of this already-identified risk group of women, and these women are in the physicians' focus during succeeding pregnancy.

However, the energetic debate about the value of detecting and treating GDM lasts until today while the issue was whether the unfavorable perinatal outcomes in pregnancies of women with hyperglycemia less than diagnostic of diabetes mellitus are independently associated with maternal glycemia or attributable to more significant obesity, higher maternal age, more urinary tract infections, or social disadvantages. The second challenge was whether treating hyperglycemia in women with GDM actually reduced adverse outcomes.

Prof. Dr. Marina Ivanišević

Guest Editor

Oral Glucose Tolerance Test in Pregnancy
Obesity in Pregnancy
Insulin Resistance
Oral Antidiabetic Drugs in Pregnancy
Insulin in the Treatment of GDM
Management of GDM
Delivery in GDM Pregnancy
Fetal Malformations
Fetal Overgrowth
New Technologies in Surveillance of GDM Pregnancy
Diagnostic Criteria of Gestational Diabetes
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (1 Paper)
Open Access Communication
Pre-pregnancy BMI but not mild stress directly influences Interleukin-6 levels and insulin sensitivity during late pregnancy
Ilena Bauer, Franziska Schleger, Julia Hartkopf, Ralf Veit, ... Louise Fritsche
Front. Biosci. (Landmark Ed) 2022, 27(2), 056;
(This article belongs to the Special Issue Gestational Diabetes)
Back to top